Divis Laboratories Ltd

Divi's Lab. | 532488

Market Closed

₹6,518.50

+₹0.00 (+0.11%)

As on 18/11/25, 10:37 PM

Market Cap1,72,859.87 CR

Current Price₹6,518.5

High / Low₹7,071.5 / 4,955

PE Ratio69.82

Book Value₹564.87

Dividend Yield0.52%

ROCE20.42%

ROE15.57%

Face Value₹2.00

Current Vol.2,42,726

Average Vol.12,76,53,456

ISININE361B01024

PB Ratio10.22

Debt to Equity0

Net Profit Margin23.41

Operating Margin35.48

Stock cgart

Stock Performance

₹2,480₹2,490

₹2,500

Previous CloseToday's Open

₹1,800₹3,000

₹2,500

52W Low52W High

₹2,480Today's Open

₹2,490Previous Close

12,00,000Volume

₹1,80052W Low

₹3,00052W High

Ratios

No data available

About Company

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals
The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries
It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports
In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management
It is among the largest pharmaceutical companies in India with a portfolio of approx
160 products across diverse therapeutic areas
Presently, it has 6 manufacturing facilities and market presence across several countries
The company has two subsidiaries M/s
Divis Laboratories (USA) Inc
, in the United States of America and M/s

Research Calls

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

;

Technical Indicators

RSI50.21

SMA 206616.38

SMA 506294.38

SMA 1006386.93

SMA 2006203.94

SMA 106652.30

MACD_12_26_Days68.48

EMA10Day6588.52

EMA20Day6556.15

EMA50Day6422.79

MACD_12_26_9_Days-39.86

EMA100Day6347.01

EMA200Day6150.91

Pivot Points

Volume Analysis

Growth Rate

Revenue Growth19.31%

ROE15.35%

EBITDA Margin35.48%

All figures in ₹ Crores

Indicators	2025	2024	2023	2022	2021
Revenue	9,360.00	7,845.00	7,767.51	8,959.83	6,969.40
Interest	2.00	3.00	0.67	0.80	0.87
Expenses	6,392.00	5,640.00	5,399.69	5,077.89	4,109.46
Financing Profit	3,320.00	2,544.00	2,712.48	3,995.81	2,922.50
Financing Margin %	35%	32%	35%	45%	42%
Other Income	352.00	339.00	344.66	113.87	62.56
Depreciation	402.00	378.00	343.18	311.51	255.59
Profit before tax	2,916.00	2,163.00	2,368.63	3,683.50	2,666.04
Tax %	25%	26%	23%	20%	26%
Net Profit	2,191.00	1,600.00	1,823.38	2,960.45	1,984.29
EPS in Rs	82.53	60.27	68.69	111.52	74.75

Show % Change

ShareHolding

📊

No Information Available

No shareholding data available at this time.

Deal	Date	Type	Quantity	Price	Traded %
GOLDMAN SACHS BANK EUROPE SE - ODI	09 Oct ‘25	Purchase	33,108	₹6,120.5	9.84%
GOLDMAN SACHS (SINGAPORE) PTE - ODI	09 Oct ‘25	Sell	33,108	₹6,120.5	9.84%
THE MTBJ LTD.AS TRST FOR GOVERNMENT PENSION INVESTMENT FUND MTBJ400045849	14 Jul ‘25	Purchase	21,874	₹6,835	2.26%
THE MTBJ LTD. AS TRST FOR GOVRNMNT PENSION INVSTMNT FUND MTBJ400045828	14 Jul ‘25	Sell	21,874	₹6,835	2.26%
PI OPPORTUNITIES AIF V LLP	06 Nov ‘24	Purchase	80,324	₹5,979.65	12.97%
PRAZIM TRADING AND INVESTMENT COMPANY PRIVATE LIMITED	06 Nov ‘24	Sell	80,324	₹5,979.65	12.97%
ISHARES CORE MSCI EMERGING MARKETS ETF	14 Nov ‘22	Purchase	2,09,124	₹3,271.4	19.33%
ISHARES CORE EMERGING MARKETS MAURITIUS CO	14 Nov ‘22	Sell	2,09,124	₹3,271.4	19.33%
ISHARES CORE MSCI EMERGING MARKETS ETF	03 Nov ‘22	Purchase	2,09,125	₹3,781.45	48.39%
ISHARES CORE EMERGING MARKETS MAURITIUS CO	03 Nov ‘22	Sell	2,09,125	₹3,781.45	48.39%

News

📊

No Information Available

No news available for this company.

Record Date

Corporate Action

Information

Announcement Day

11 Aug 2025

AGM

17 May 2025

25 Jul 2025

Final Dividend (₹30)

As per enclosed letter. Recommended a final dividend of 30/- (i.e. 1,500%) per equity share of face value 2/-each for the financial year 2024-25, subject to approval of the members at the ensuing 35th Annual General Meeting (AGM). The dividend shall be paid within specified timelines from the conclusion of the AGM. The 35th AGM of the Members of the Company will be held on Monday, August 11, 2025. The record date for the purpose of the payment of dividend is July 25, 2025.

17 May 2025

12 Aug 2024

AGM

25 May 2024

02 Aug 2024

Final Dividend (₹30)

As per enclosed letter. Recommended a final dividend of ? 30/- (i.e. 1,500%) per equity share of face value ? 2/- each for the financial year 2023-24, subject to approval of the members at the ensuing 34th Annual General Meeting (AGM). The dividend shall be paid within specified timelines from the conclusion of the AGM

25 May 2024

28 Aug 2023

AGM

03 Jul 2023

11 Aug 2023

Final Dividend (₹30)

Recommended a Dividend of ? 30/- (i.e. 1,500%) per equity share of face value ? 2/- each for the financial year 2022-23, subject to approval of the members at the ensuing 33rd Annual General Meeting (AGM). The dividend shall be credited / warrants thereof dispatched within specified timelines from the conclusion of the AGM. The AGM date and record date for the purpose of the payment of dividend will be announced in due course.

20 May 2023

22 Aug 2022

AGM

04 Jul 2022

12 Aug 2022

Final Dividend (₹30)

Divis Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 23, 2022, inter alia, has recommended a Dividend of Rs. 30/- (i.e. 1500%) per equity share of face value Rs. 2/- each for the financial year 2021-22, subject to approval of the members at the ensuing 32nd Annual General Meeting (AGM). The dividend shall be credited/ warrants thereof dispatched within 30 (thirty) days from the conclusion of the AGM.

23 May 2022

30 Aug 2021

AGM

19 Jul 2021

20 Aug 2021

Final Dividend (₹20)

As per enclosed

29 May 2021

Peers

LTP(₹)	Market Cap(₹ Cr.)	P/E Ratio(Ratio)	P/B Ratio(Ratio)	Cash Earnings(Ratio)	Debt to Equity(Ratio)	Net Profit Ratio(%)
6,475	1,71,898	69	11	59	0	23.41%
1,760	4,22,211	37	5	30	0	20.88%
3,793	1,28,372	59	15	43	1	16.60%
1,515	1,22,349	22	4	19	0	19.21%
1,244	1,03,789	18	3	14	0	17.54%
2,047	93,506	22	5	17	0	14.56%
928	93,404	19	4	15	0	19.86%
2,224	91,800	53	6	35	0	14.39%
1,240	72,630	21	2	14	0	10.98%
5,711	68,288	29	5	25	0	17.09%

Showing 10 of 124 Results

#IndiaInvests

Trusted by 2.5 lac + Indians for their wealth-building needs

Invest in stocks with ease

Open your account in less than 10 mins*

By proceeding, you agree to all T&C *

Top Gainers

Top Losers

Frequently Asked Questions

What is Share Price of Divis Laboratories Ltd?

The current share price of Divis Laboratories Ltd (Divi's Lab.) is ₹6518.50. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of Divis Laboratories Ltd?

The Price-to-Earnings (P/E) ratio of Divis Laboratories Ltd is 6518.50. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of Divis Laboratories Ltd?

Divis Laboratories Ltd has a 52-week high of ₹7071.50 and a 52-week low of ₹4955.00. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of Divis Laboratories Ltd?

Divis Laboratories Ltd offers a dividend yield of 0.46%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of Divis Laboratories Ltd?

The Earnings Per Share (EPS) of Divis Laboratories Ltd is ₹93.61. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of Divis Laboratories Ltd?

Divis Laboratories Ltd has a Return on Equity (ROE) of 15.57%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

Ready to invest smarter?
Download the app today.

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

App Store

4.2

Discover our app's power in seconds.